NR3C1 and prostate carcinoma: Accordingly, it has been shown that the mere overexpression of GR is enough to decrease the proliferation rate of prostate cancer cells expressing AR [99], and the activation of the GR by cognate agonists attenuates the expression of androgen-activated AR genes [97], emphasizing the tumour suppressor function of GR on AR.